StreetInsider.com News Articles

Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Tue, 08 Sep 2026 09:00:00 -0400

Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York

Cambridge, Massachusetts--(Newsfile Corp. - September 8, 2026) - Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to work across many viruses, today announced that Rick Pierce, Chief Executive Officer, will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, taking place September 9 and 10, 2026 in New York City.

Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Details of the presentation

Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

Tue, 08 Sep 2026 09:00:00 -0400

Rick Pierce, Chief Executive Officer, to deliver an investor presentation on Thursday, September 10 in New York

Mr. Pierce will deliver a corporate overview and participate in one-on-one meetings with investors during the conference.

Details of the presentation

Form SCHEDULE 13G Decoy Therapeutics Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26926170.html

Form SCHEDULE 13G Decoy Therapeutics Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260814/26926170.html

Form 10-Q Decoy Therapeutics Inc. For: Jun 30

Wed, 12 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26912890.html

Form 10-Q Decoy Therapeutics Inc. For: Jun 30

Wed, 12 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26912890.html

Form DEF 14A Decoy Therapeutics Inc. For: Sep 14

Tue, 04 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260804/26867627.html

Form DEF 14A Decoy Therapeutics Inc. For: Sep 14

Tue, 04 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260804/26867627.html

Form DEFA14A Decoy Therapeutics Inc.

Tue, 04 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260804/26866263.html

Form DEFA14A Decoy Therapeutics Inc.

Tue, 04 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260804/26866263.html

Decoy Therapeutics expands patent portfolio to 7 families, 19 apps

Mon, 03 Aug 2026 09:02:21 -0400

Decoy Therapeutics Inc. (Nasdaq: DCOY) announced an expansion of its intellectual property portfolio, which now covers seven patent families and 19 pending applications across seven jurisdictions, according to a company statement.

The portfolio includes one granted U.S. patent and pending applications filed in the United States, Australia, Canada, China, Europe, Japan, and New Zealand. All patents and applications are solely owned by the Cambridge, Mass.-based biotechnology company.

The granted patent, U.S. Patent No. 12,226,474, titled "Methods and Compositions for Treating Infections," covers antiviral peptide conjugates comprised of one or more viral spike protein sequences that include D-amino acids.

The portfolio spans four main

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Mon, 03 Aug 2026 09:00:00 -0400

Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design platform behind them

CAMBRIDGE, Mass., Aug. 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion of its intellectual property portfolio, which now comprises seven patent families covering compositions of matter, methods of manufacture, formulations, and the company's IMP³ACT™ design platform.

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Mon, 03 Aug 2026 09:00:00 -0400

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Mon, 03 Aug 2026 09:00:00 -0400

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

Mon, 03 Aug 2026 09:00:00 -0400

Form 3 Decoy Therapeutics Inc. For: Jul 14 Filed by: Gauthier Patricia G.

Fri, 31 Jul 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260731/26851447.html

Form 3 Decoy Therapeutics Inc. For: Jul 14 Filed by: Gauthier Patricia G.

Fri, 31 Jul 2026 16:52:00 -0400

si-local-file:///var/storage/secattach/20260731/26851447.html

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire

Mon, 27 Jul 2026 09:01:05 -0400

Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.

The candidate was engineered on Decoy's IMP3ACT™ platform to block coronavirus entry, where it has shown nanomolar to picomolar activity across known coronavirus strains. Its activity against Ebola Zaire, a filovirus responsible for 17 of the last 20 Ebola outbreaks, demonstrates the value of the

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

CAMBRIDGE, Mass., July 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its D-MAV candidates demonstrates in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute. Building on the result, Decoy has opened an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

Mon, 27 Jul 2026 09:00:00 -0400

Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the
platform; opens a new program in filovirus pandemic preparedness

Form PRE 14A Decoy Therapeutics Inc. For: Jul 24

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813570.html

Form PRE 14A Decoy Therapeutics Inc. For: Jul 24

Fri, 24 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260724/26813570.html

Form EFFECT Decoy Therapeutics Inc.

Mon, 20 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260720/26786498.html